Connor, Clark & Lunn Investment Management (CC&L)
CRL icon

Connor, Clark & Lunn Investment Management (CC&L)’s Charles River Laboratories CRL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-54,570
Closed -$9.41M – 1660
2026
Q1 		$9.41M Sell
54,570
-79,586
-59% -$14.8M 0.02% 485
2025
Q4 		$26.8M Sell
134,156
-46,408
-26% -$8.42M 0.07% 235
2025
Q3 		$28.3M Sell
180,564
-10,704
-6% -$1.7M 0.09% 201
2025
Q2 		$29M Buy
191,268
+166,429
+670% +$22.2M 0.1% 177
2025
Q1 		$3.74M Buy
+24,839
New +$4.16M 0.02% 576
2024
Q1 		– Sell
-17,027
Closed -$4.03M – 1553
2023
Q4 		$4.03M Buy
+17,027
New +$3.35M 0.02% 490
2022
Q3 		– Sell
-16,923
Closed -$3.62M – 1131
2022
Q2 		$3.62M Sell
16,923
-9,110
-35% -$2.23M 0.02% 370
2022
Q1 		$7.39M Sell
26,033
-18,986
-42% -$5.85M 0.04% 262
2021
Q4 		$17M Buy
45,019
+19,233
+75% +$7.47M 0.08% 182
2021
Q3 		$10.6M Buy
25,786
+18,446
+251% +$7.66M 0.06% 236
2021
Q2 		$2.71M Buy
+7,340
New +$2.45M 0.01% 482
2020
Q2 		– Sell
-8,396
Closed -$1.06M – 1045
2020
Q1 		$1.06M Buy
+8,396
New +$1.26M 0.01% 549
2019
Q1 		– Sell
-2,200
Closed -$249K – 934
2018
Q4 		$249K Buy
+2,200
New +$275K ﹤0.01% 815
2018
Q2 		– Sell
-6,575
Closed -$702K – 1047
2018
Q1 		$702K Buy
+6,575
New +$709K ﹤0.01% 527
2017
Q4 		– Sell
-10,400
Closed -$1.12M – 794
2017
Q3 		$1.12M Buy
+10,400
New +$1.07M 0.01% 511
2016
Q4 		– Sell
-3,300
Closed -$275K – 901
2016
Q3 		$275K Buy
+3,300
New +$277K ﹤0.01% 689
2014
Q4 		– Sell
-17,500
Closed -$1.04M – 595
2014
Q3 		$1.04M Buy
17,500
+3,900
+29% +$223K 0.01% 295
2014
Q2 		$775K Buy
+13,600
New +$746K 0.01% 346
2013
Q3 		– Sell
-5,300
Closed -$229K – 537
2013
Q2 		$229K Buy
+5,300
New +$227K ﹤0.01% 459

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CRL Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 54,570 shares — an estimated $9.41M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CRL in Q2 2013 and held it in 19 quarters. The position peaked at $29M in Q2 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 54,570 Charles River Laboratories shares in Q2 2026, an estimated $9.41M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Charles River Laboratories in Q2 2013 and held it in 19 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Charles River Laboratories position peaked at $29M in Q2 2025.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.